Delirium tremens is the most severe manifestation of alcohol withdrawal syndrome (AWS), characterized by rapid-onset fluctuating delirium with severe autonomic hyperactivity, typically occurring 48–96 hours after the last drink, with a mortality rate of 1–4% among hospitalized patients when treated, and historically up to 15% when untreated. [2-4] It occurs in approximately 3–5% of patients hospitalized for alcohol withdrawal. [3][5]
1. History
- Time of last drink — the single most critical HPI element; DT onset is typically 48–96 hours after cessation, peaking around day 3–5 [6-7]
- Quantity, frequency, and duration of alcohol use (daily amount in standard drinks, years of heavy use)
- Prior withdrawal episodes — specifically ask about prior DT, withdrawal seizures, or ICU admissions (strongest predictor of recurrence) [3][6]
- Prior detox attempts — number and outcomes; kindling effect makes successive withdrawals progressively more severe [6]
- Concurrent substance use — benzodiazepines, barbiturates, opioids, stimulants (co-withdrawal from GABAergic agents dramatically increases risk) [6]
- Symptom progression — tremor → anxiety/insomnia → hallucinations → seizures → confusion/disorientation (not all patients progress sequentially) [6]
- Nutritional status — recent oral intake, vomiting, weight loss (risk for Wernicke encephalopathy) [8]
- Important negatives — head trauma, fever source, recent medication changes, suicidal ideation
2. Alarm Features
- Agitated delirium with disorientation, visual hallucinations, and severe autonomic instability [2-3]
- Seizures — generalized tonic-clonic; if untreated, ~1/3 of patients with withdrawal seizures progress to DT [4]
- Hyperthermia >38.3°C (death in DT is often from hyperthermia, cardiac arrhythmias, or complications of seizures) [3]
- Refractory agitation despite escalating benzodiazepine doses
- Status epilepticus
- Focal neurological deficits (suggests alternative etiology — stroke, subdural hematoma, CNS infection) [6]
- Hemodynamic instability — SBP >180 or <90, HR >130
- Respiratory depression from over-sedation or aspiration
3. Medications
First-line treatment
- Benzodiazepines — cornerstone of DT management [6][9]
- Diazepam 5–10 mg IV q10–15 min until light somnolence achieved (long-acting, rapid onset) [5]
- Lorazepam 2–4 mg IV q10–15 min (preferred in hepatic impairment — no active metabolites) [2][5]
- Very high doses may be required (documented up to 260–480 mg/day diazepam in refractory cases) [6][10]
Adjunctive agents
- Phenobarbital — adjunct to benzodiazepines when DT is not adequately controlled; can also be used as monotherapy but narrower therapeutic window [5-6]
- Dexmedetomidine — ICU adjunct; may reduce intubation need but does not address underlying GABA pathophysiology [2][11]
- Propofol — for benzodiazepine-resistant withdrawal requiring intubation [11]
- Antipsychotics (haloperidol, quetiapine, risperidone) — adjunct only for persistent hallucinations/agitation; never as monotherapy (lower seizure threshold) [6]
Contraindicated/avoid
- Alpha2-agonists and beta-blockers as monotherapy for DT [6]
- QT-prolonging drugs (63% of DT patients have prolonged QTc) [12]
- Paraldehyde [6]
Cautions
- Monitor for propylene glycol toxicity (hyponatremia, metabolic acidosis) with high-dose IV lorazepam or diazepam [6]
- Benzodiazepines may precipitate hepatic encephalopathy in advanced liver disease [2][13]
4. Diet
- NPO initially in severe DT due to aspiration risk from altered mental status
- IV fluids — aggressive hydration with dextrose-containing fluids; correct dehydration from diaphoresis, vomiting, poor oral intake [3][6]
- Thiamine before or concurrent with glucose — administer thiamine 100 mg IV/IM daily for 3–5 days to prevent Wernicke encephalopathy; in suspected WE, high-dose thiamine (200–500 mg IV q8h) is recommended [6][8][14]
- Electrolyte repletion — correct potassium, magnesium (supplement if hypomagnesemia, arrhythmias, or seizure history), phosphorus (supplement if <1 mg/dL) [6]
- Folate 400–1000 µg IV daily for critically ill patients [14-15]
- Advance diet as mental status clears; chronic alcoholics are often severely malnourished
5. Review of Systems
- Neuro: tremor, seizures, hallucinations (visual > auditory > tactile), confusion, headache, gait instability
- Psych: anxiety, agitation, paranoia, insomnia, nightmares
- GI: nausea, vomiting, abdominal pain (pancreatitis, GI bleed, hepatitis)
- CV: palpitations, chest pain (arrhythmia, cardiomyopathy)
- Pulmonary: dyspnea, cough (aspiration pneumonia)
- MSK: falls, trauma history
- Constitutional: fever, diaphoresis, weight loss, anorexia
6. Collateral History and Family History
- Collateral from family/friends is essential when the patient is delirious and cannot provide history — confirm last drink, typical daily intake, prior withdrawal complications [6]
- EMS/police — circumstances of presentation, witnessed seizures, trauma
- Family history of alcohol use disorder (strong genetic component — heritability ~50%)
- Social context — housing status (homelessness predicts inability to complete outpatient withdrawal), employment, support system, prior treatment engagement [16]
7. Risk Factors
- Prior DT or withdrawal seizures — the strongest predictor (LR 2.9 for DT) [4][6]
- Multiple prior withdrawal episodes (kindling effect) [6]
- CIWA-Ar ≥15 with SBP >150 or HR >100 [3]
- Age >65 [6][17]
- Long duration of heavy daily alcohol use [6]
- Comorbid medical/surgical illness (especially traumatic brain injury) [6][17]
- Concurrent GABAergic drug dependence (benzodiazepines, barbiturates) [6]
- Positive BAC with concurrent withdrawal symptoms [6]
- Electrolyte abnormalities — hypokalemia, hypomagnesemia [3]
- Low platelet count, elevated ALT [6]
- Baseline CIWA-Ar ≥10 (OR 6.05 for progression to DT in trauma patients) [17]
The following table from a JAMA systematic review summarizes the predictive accuracy of clinical findings for severe alcohol withdrawal and DT: [4]
8. Differential Diagnosis
Must rule out mimics before attributing delirium solely to alcohol withdrawal: [6][18]
- Wernicke encephalopathy — classic triad of oculomotor dysfunction, ataxia, encephalopathy (present in <1/3 of cases); can coexist with DT [8]
- Hepatic encephalopathy — asterixis, elevated ammonia, chronic liver disease
- Hypoglycemia / Diabetic ketoacidosis [6]
- CNS infection (meningitis, encephalitis) — fever + altered mental status; low threshold for LP
- Subdural hematoma / Intracranial hemorrhage — alcoholics are at high risk for falls and coagulopathy
- Sepsis — common in malnourished, immunocompromised alcoholics
- Thyrotoxicosis [18]
- Anticholinergic toxicity / Sympathomimetic toxicity
- Benzodiazepine or sedative-hypnotic withdrawal (may co-occur) [6]
- Alcohol hallucinosis — auditory hallucinations with clear sensorium (no delirium); distinct from DT [6]
- Nonconvulsive status epilepticus
- Hyponatremia
9. Past Medical History
- Prior episodes of DT, withdrawal seizures, or complicated withdrawal
- Chronic liver disease / cirrhosis (affects drug metabolism — prefer lorazepam/oxazepam) [2]
- Pancreatitis, GI bleeding (variceal or peptic)
- Cardiomyopathy (alcoholic)
- Seizure disorder (independent of withdrawal)
- Psychiatric comorbidities — depression, anxiety, PTSD, other substance use disorders [6]
- Traumatic brain injury [6]
- Prior surgical history (recent surgery/hospitalization may precipitate unrecognized withdrawal)
10. Physical Exam
Vital signs
- Tachycardiahypertensionhyperthermiatachypnea[2-3]
Focused exam
- Neuro: coarse tremor (often severe, visible at rest), hyperreflexia, clonus, nystagmus (Wernicke), gait ataxia, orientation assessment, pupil exam
- Mental status: fluctuating confusion, disorientation to time/place/person, visual hallucinations (classically insects, animals), agitation, combativeness [3]
- Skin: diaphoresis, pallor, jaundice, spider angiomata, palmar erythema, signs of trauma
- Abdomen: hepatomegaly, ascites, tenderness (pancreatitis, peritonitis)
- CV: irregular rhythm (atrial fibrillation common in alcoholics), murmurs
- Head/face: signs of trauma, Battle sign, raccoon eyes
11. Lab Studies
Per ASAM guidelines, the following should be obtained and treatment should not be delayed while awaiting results: [6]
- CBC — thrombocytopenia (predictor of severe AWS), macrocytosis (MCV), leukocytosis [4][19]
- CMP — glucose, electrolytes (K⁺, Mg²⁺, PO₄³⁻, Na⁺), BUN/Cr, hepatic panel (AST, ALT, bilirubin, albumin) [6][20]
- Magnesium and phosphorus levels [6]
- Blood alcohol concentration (BAC) — positive BAC with withdrawal symptoms indicates severe dependence [6]
- Lactate — if sepsis or alcoholic ketoacidosis suspected
- Ammonia — if hepatic encephalopathy suspected [20]
- Lipase — if pancreatitis suspected
- Coagulation studies (PT/INR) — liver synthetic function
- Blood cultures — if febrile
- Urinalysis and urine drug screen — identify co-ingestions
- Thyroid function — if thyrotoxicosis considered [18]
- ABG/VBG — if metabolic acidosis suspected (alcoholic ketoacidosis, propylene glycol toxicity)
12. Imaging
- CT head without contrast — obtain if focal neurological deficits, new-onset seizures, seizure pattern change, head trauma, or failure to improve with treatment [6]
- Chest X-ray — if aspiration pneumonia, respiratory distress, or fever workup
- Imaging is not routinely required if presentation is classic for DT with known history and no focal findings [6]
- MRI brain — if Wernicke encephalopathy suspected (mammillary body and periaqueductal gray signal changes)
13. Special Tests
Scoring systems
- CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol–Revised) — widely used to guide symptom-triggered therapy; scores 0–67. Not recommended in patients with active delirium (relies on patient-reported symptoms) [6]
- PAWSS (Prediction of Alcohol Withdrawal Severity Scale) — best validated tool for predicting severe AWS; score ≥4 has LR 174 for complicated withdrawal [4][6]
- CAM-ICU — preferred for monitoring delirium in DT patients [6]
- RASS (Richmond Agitation-Sedation Scale) — useful for titrating sedation to target light somnolence [5-6]
- GMAWS (Glasgow Modified Alcohol Withdrawal Scale) — objective, does not rely on patient self-report
Point-of-care
- Bedside glucose
- Point-of-care electrolytes
- Bedside ultrasound (IVC for volume status, cardiac function)
Procedures
- Lumbar puncture if meningitis/encephalitis cannot be excluded
- EEG if nonconvulsive status epilepticus suspected [6]
14. ECG
- Obtain ECG on all patients with DT — death from cardiac arrhythmias is a leading cause of mortality [3]
- QTc prolongation — present in 63% of patients with DT/withdrawal seizures; acquired long QT syndrome [12]
- Tachyarrhythmias — sinus tachycardia (most common), atrial fibrillation, SVT, ventricular tachycardia, torsades de pointes [12]
- Avoid QT-prolonging medications (haloperidol, ondansetron) when QTc is prolonged [12]
- Electrolyte-related changes — U waves (hypokalemia), peaked T waves (hyperkalemia), ST changes
15. Assessment
Clinical summary: DT represents CNS hyperexcitability from abrupt removal of alcohol's GABAergic effects combined with upregulated glutamatergic (NMDA) activity. [3] It is a medical emergency requiring ICU-level care.
Severity stratification
- CIWA-Ar <8: mild (unlikely DT)
- CIWA-Ar 8–15: moderate
- CIWA-Ar ≥19: severe — high risk for seizures and DT [3][6]
- Active DT: use CAM-ICU and RASS rather than CIWA-Ar [6]
Typical presentation: Agitated, diaphoretic, tremulous patient with visual hallucinations, disorientation, tachycardia, hypertension, and fever, 2–4 days after last drink [3][5]
Atypical presentations: Elderly patients may present later or with less autonomic hyperactivity; patients on beta-blockers may mask tachycardia; concurrent medical illness may obscure the diagnosis [6]
Complications: Aspiration pneumonia, rhabdomyolysis, cardiac arrhythmias (torsades), status epilepticus, self-injury, iatrogenic over-sedation, Wernicke encephalopathy, death [3-4]
16. Treatment Plan
Initial stabilization (ED)
- ABCs, IV access, continuous monitoring (telemetry, pulse oximetry)
- Administer thiamine 100 mg IV before or with glucose [6]
- Aggressive IV fluid resuscitation
- Correct electrolytes (K⁺, Mg²⁺, PO₄³⁻)
Pharmacotherapy — Benzodiazepines (first-line): [5-6]
- Diazepam 5–10 mg IV q10–15 min, titrate to light somnolence
- Lorazepam 2–4 mg IV q10–15 min (hepatic impairment)
- Goal: patient calm, cooperative, with tendency to fall asleep unless stimulated [6]
- Do not hesitate to use very high doses if needed [6][10]
Benzodiazepine-resistant DT: [6][11]
- Phenobarbital 130–260 mg IV as adjunct (monitor for respiratory depression)
- Propofol infusion if intubated
- Midazolam continuous infusion in ICU
- Dexmedetomidine as adjunct (does not address GABA pathophysiology)
If delirium persists >72 hours: Consider benzodiazepine-induced delirium; reduce benzodiazepine dose and add low-dose antipsychotic (quetiapine, risperidone, or haloperidol — check QTc first) [6]
Supportive care: [3][6]
- Quiet, well-lit room; frequent reorientation
- 1:1 nursing observation for agitated/disoriented patients
- Restraints only when necessary for safety
- Thiamine 100–500 mg IV daily × 3–5 days
- Folate 1 mg IV daily
- Multivitamin supplementation
17. Disposition
ICU admission criteria (essentially all DT patients): [3][6][16]
- Active delirium tremens
- CIWA-Ar ≥20 or refractory symptoms
- Requirement for frequent IV benzodiazepine dosing
- Hemodynamic instability
- Need for intubation/mechanical ventilation
- Significant comorbid medical conditions (GI bleed, pancreatitis, sepsis)
Inpatient (non-ICU) may be appropriate for: [16]
- Moderate withdrawal (CIWA-Ar 10–18) with risk factors for DT
- History of DT/seizures without current severe symptoms
- Inability to tolerate oral medications
Discharge criteria (from hospital, not from ED)
- Resolution of delirium
- Stable vital signs for ≥24 hours
- Tolerating oral medications and nutrition
- CIWA-Ar consistently <8
- Safe disposition plan with follow-up arranged
Specialist consultation triggers
- Toxicology/addiction medicine for refractory cases
- Neurology if seizures are atypical or focal
- Gastroenterology/hepatology if concurrent liver failure
- Psychiatry for co-occurring psychiatric disorders
18. Follow Up / Return Precautions
- Follow-up within 1–2 days of hospital discharge with primary care or addiction medicine [6]
- Addiction treatment referral — initiate discussion about medications for AUD (naltrexone, acamprosate, disulfiram) before discharge [2]
- Return precautions: return immediately for recurrent confusion, seizures, fever, persistent vomiting, chest pain, or inability to take medications/fluids
- Expected recovery: DT typically resolves within 2–3 days (range 1–8 days) with appropriate treatment; residual anxiety, insomnia, and mild autonomic symptoms may persist for weeks [3]
- Patient counseling: emphasize that each subsequent withdrawal episode carries higher risk of DT (kindling); abstinence is the safest approach; connect with support services (AA, SMART Recovery, social work) [6]
- Outpatient thiamine 100 mg PO daily should be continued [2]
References
1. Management of Alcohol Withdrawal Syndrome in Patients With Alcoholic Liver Disease. — Chand PK, Panda U, Mahadevan J, Murthy P. Journal of Clinical and Experimental Hepatology. 2022.
2. Identification and Treatment of Alcohol Use Disorder. — Haber PS. The New England Journal of Medicine. 2025.
3. Recognition and Management of Withdrawal Delirium (Delirium Tremens). — Schuckit MA. The New England Journal of Medicine. 2014.
4. Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?The Rational Clinical Examination Systematic Review. — Wood E, Albarqouni L, Tkachuk S, et al. The Journal of the American Medical Association. 2018.
5. Managing Selected Chronic Conditions in Hospitalized Patients. — Gauer RL, Abellada A, Stewart M, Kozloski R. American Family Physician. 2024.
6. Clinical Practice Guideline on Alcohol Withdrawal Management. — Anika Alvanzo MD MS DFASAM FACP, Kurt Kleinschmidt MD FASAM, Julie A. Kmiec DO FASAM, et al American Society of Addiction Medicine (2020). 2020.
7. Alcohol Withdrawal Syndrome: Outpatient Management. — Tiglao SM, Meisenheimer ES, Oh RC. American Family Physician. 2021.
8. A Case for Early High-Dose Thiamine—Moving From Reaction to Prevention. — Goldstein DN, Hunter AJ, Riquelme PA. JAMA Internal Medicine. 2025.
9. The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. — Perry C, Liberto J, Milliken C, et al. Annals of Internal Medicine. 2022.
10. Successful Treatment of Severe Alcohol Withdrawal Delirium With Very High-Dose Diazepam (260-480 mg) Administration. — Korkmaz ŞA, Aldemir E, Güleç Öyekçin D. Current Medical Research and Opinion. 2024.
11. The Emergency Medicine Management of Severe Alcohol Withdrawal. — Long D, Long B, Koyfman A. The American Journal of Emergency Medicine. 2017.
12. ECG Changes Amongst Patients With Alcohol Withdrawal Seizures and Delirium Tremens. — Cuculi F, Kobza R, Ehmann T, Erne P. Swiss Medical Weekly. 2006.
13. ACG Clinical Guideline: Alcohol-Associated Liver Disease. — Jophlin LL, Singal AK, Bataller R, et al. The American Journal of Gastroenterology. 2024.
14. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. — Flannery AH, Adkins DA, Cook AM. Critical Care Medicine. 2016.
15. Prevention of Alcohol Withdrawal Syndrome in the Surgical ICU: An American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. — Seshadri A, Appelbaum R, Carmichael SP, et al. Trauma Surgery & Acute Care Open. 2022.
16. Management of Substance Use Disorder (SUD) (2021). — Timothy Atkinson PharmD, Charolotte Baldridge FNP, Jennifer Burden PhD MS, et al Department of Veterans Affairs. 2021.
17. Occurrence, Predictors, and Prognosis of Alcohol Withdrawal Syndrome and Delirium Tremens Following Traumatic Injury. — Salottolo K, McGuire E, Mains CW, van Doorn EC, Bar-Or D. Critical Care Medicine. 2017.
18. Management of Alcohol Use Disorder: A Gastroenterology and Hepatology-Focused Perspective. — Díaz LA, König D, Weber S, et al. The Lancet. Gastroenterology & Hepatology. 2025.
19. Biochemical, Hematological, Inflammatory, and Gut Permeability Biomarkers in Patients With Alcohol Withdrawal Syndrome With and Without Delirium Tremens. — Melamud MM, Bobrik DV, Brit PI, et al. Journal of Clinical Medicine. 2024.
20. A Clinical Prediction Model for Delirium Tremens: Development and Validation in Alcohol-Dependent Patients Using Multivariable Logistic Regression. — Zhong J, Huang X, Yao X. Frontiers in Psychiatry. 2025.